Knockdown of eukaryotic translation initiation factor 4E suppresses cell growth and invasion, and induces apoptosis and cell cycle arrest in a human lung adenocarcinoma cell line Corrigendum in /10.3892/mmr.2016.4930

Chen,Baofu; Zhang,Bo; Xia,Lilong; Zhang,Jian; Chen,Yu; Hu,Quanteng; Zhu,Chengchu

doi:10.3892/mmr.2015.4468

Knockdown of eukaryotic translation initiation factor 4E suppresses cell growth and invasion, and induces apoptosis and cell cycle arrest in a human lung adenocarcinoma cell line

Corrigendum in: /10.3892/mmr.2016.4930

Authors:
- Baofu Chen
- Bo Zhang
- Lilong Xia
- Jian Zhang
- Yu Chen
- Quanteng Hu
- Chengchu Zhu
View Affiliations

Affiliations: Department of Thoracic Surgery, Taizhou Hospital, Wenzhou Medical University, Linhai, Zhejiang 317000, P.R. China, Department of Thoracic Surgery, Zhejiang Hospital, Hangzhou, Zhejiang 310013, P.R. China
Published online on: October 21, 2015 https://doi.org/10.3892/mmr.2015.4468
Pages: 7971-7978
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Eukaryotic translation initiation factor 4E (eIF4E) was shown to be upregulated in malignant human tumors. To assess the effect of downregulation of eIF4E on the proliferation and invasiveness of a human lung adenocarcinoma cell line, a short hairpin (sh)RNA targeting eIF4E was constructed and transfected into A549 human lung adenocarcinoma cells. The expression of eIF4E was determined by reverse transcription‑quantitative polymerase chain reaction and western blotting. Cell viability was assessed using a Cell Counting kit‑8, and apoptosis levels and cell cycle distribution were assessed by flow cytometry. Invasiveness was assessed using Transwell chambers. Transfection of the A549 cells with eIF4E targeting shRNA reduced the mRNA and protein expression levels of eIF4E by >70% 48 and 72 h following transfection, and eIF4E targeting shRNA‑transfected cells were significantly less viable compared with the cells transfected with scrambled shRNA. The rate of apoptosis was also significantly increased, significantly more cells were in the G0/G1 phase and fewer were in the S phase, indicating cell cycle arrest. The fraction of transfected cells migrating across Transwell inserts were also reduced. In conclusion, inhibition of eIF4E suppressed cell growth and invasion, induced apoptosis and cell cycle arrest, suggesting that eIF4E may be a potential therapeutic target in lung adenocarcinoma.

View Figures

View References

1	WHO international agency for research on cancer: Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012.
2	Joshi B, Cameron A and Jagus R: Characterization of mammalian eIF4E-family members. Eur J Biochem. 271:2189–2203. 2004. View Article : Google Scholar : PubMed/NCBI
3	Ziemniak M, Strenkowska M, Kowalska J and Jemielity J: Potential therapeutic applications of RNA cap analogs. Future Med Chem. 5:1141–1172. 2013. View Article : Google Scholar : PubMed/NCBI
4	Culjkovic B, Topisirovic I and Borden KL: Controlling gene expression through RNA regulons: The role of the eukaryotic translation initiation factor eIF4E. Cell Cycle. 6:65–69. 2007. View Article : Google Scholar : PubMed/NCBI
5	Jackson RJ, Hellen CU and Pestova TV: The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 11:113–127. 2010. View Article : Google Scholar : PubMed/NCBI
6	De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene. 23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
7	Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM, Fujii T, Cordon-Cardo C, Jen J and Travis WD: Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res. 16:240–248. 2010. View Article : Google Scholar
8	Armengol G, Rojo F, Castellví J, Iglesias C, Cuatrecasas M, Pons B, Baselga J and Ramón y Cajal S: 4E-binding protein 1: A key molecular 'funnel factor' in human cancer with clinical implications. Cancer Res. 67:7551–7555. 2007. View Article : Google Scholar : PubMed/NCBI
9	Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, Baselga J and Ramon y Cajal S: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res. 13:81–89. 2007. View Article : Google Scholar : PubMed/NCBI
10	Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, Parsons SH, Brail LH, Colligan BM, Koop JW, et al: eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 69:3866–3873. 2009. View Article : Google Scholar : PubMed/NCBI
11	Graff JR, Konicek BW, Carter JH and Marcusson EG: Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68:631–634. 2008. View Article : Google Scholar : PubMed/NCBI
12	Fan S, Ramalingam SS, Kauh J, Xu Z, Khuri FR and Sun SY: Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther. 8:1463–1469. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zhang B, Zhu C, Chen B, Zhang X, Ye M and Lin A: Expression and its clinical significance of eIF4E in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 13:1132–1135. 2010.In Chinese. PubMed/NCBI
14	Li L, Lin M, Li L, Wang R, Zhang C, Qi G, Xu M, Rong R and Zhu T: Renal telocytes contribute to the repair of ischemically injured renal tubules. J Cell Mol Med. 18:1144–1156. 2014. View Article : Google Scholar : PubMed/NCBI
15	Crinò L, Weder W and van Meerbeeck J: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 5): v103–v115. 2010. View Article : Google Scholar : PubMed/NCBI
16	Sonenberg N and Hinnebusch AG: Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell. 136:731–745. 2009. View Article : Google Scholar : PubMed/NCBI
17	Rousseau D, Kaspar R, Rosenwald I, Gehrke L and Sonenberg N: Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci USA. 93:1065–1070. 1996. View Article : Google Scholar : PubMed/NCBI
18	Scapinello A, D'Amore ES, Cavazzana AO, Gramegna V and Ninfo V: Retroperitoneal cystic neuroendocrine tumor. A case report. Pathologica. 87:544–547. 1995.PubMed/NCBI
19	Graff JR and Zimmer SG: Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis. 20:265–273. 2003. View Article : Google Scholar : PubMed/NCBI
20	Topisirovic I, Ruiz-Gutierrez M and Borden KL: Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res. 64:8639–8642. 2004. View Article : Google Scholar : PubMed/NCBI
21	Phillips A and Blaydes JP: MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA. Oncogene. 27:1645–1649. 2008. View Article : Google Scholar
22	Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J and Lowe SW: Dissecting eIF4E action in tumorigenesis. Genes Dev. 21:3232–3237. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C and Pandolfi PP: The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med. 10:484–486. 2004. View Article : Google Scholar : PubMed/NCBI
24	Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J and Lowe SW: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
25	Bremaud A, West DC and Thomson AM: Binomial parameters differ across neocortical layers and with different classes of connections in adult rat and cat neocortex. Proc Natl Acad Sci USA. 104:14134–14139. 2007. View Article : Google Scholar : PubMed/NCBI
26	Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R and Mak TW: Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA. 107:13984–13990. 2010. View Article : Google Scholar : PubMed/NCBI
27	Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, et al: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 117:2638–2648. 2007. View Article : Google Scholar : PubMed/NCBI
28	Jacobson BA, Thumma SC, Jay-Dixon J, Patel MR, Dubear Kroening K, Kratzke MG, Etchison RG, Konicek BW, Graff JR and Kratzke RA: Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide. PLoS One. 8:e816692013. View Article : Google Scholar : PubMed/NCBI
29	Ramalingam S, Gediya L, Kwegyir-Afful AK, Ramamurthy VP, Purushottamachar P, Mbatia H and Njar VC: First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines. Oncotarget. 5:530–543. 2014. View Article : Google Scholar : PubMed/NCBI
30	Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA, Dowless MS, Iversen PW, Parsons S, Ellis KE, et al: Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 71:1849–1857. 2011. View Article : Google Scholar : PubMed/NCBI
31	Kentsis A, Topisirovic I, Culjkovic B, Shao L and Borden KL: Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA. 101:18105–18110. 2004. View Article : Google Scholar : PubMed/NCBI
32	Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH Jr and Borden KL: Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): A proof-of-principle clinical trial with ribavirin. Blood. 114:257–260. 2009. View Article : Google Scholar : PubMed/NCBI
33	Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, et al: Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell. 128:257–267. 2007. View Article : Google Scholar : PubMed/NCBI
34	Yang SX, Hewitt SM, Steinberg SM, Liewehr DJ and Swain SM: Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multitumor tissue microarray. Oncol Rep. 17:281–287. 2007.PubMed/NCBI
35	Helkkinen T, Korpela T, Fagerholm R, Khan S, Aittomäki K, Heikkilä P, Blomqvist C, Carpén O and Nevanlinna H: Eukayrotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer treatment phenotype and predicts survival after anthracycline chemotherapy treatment. Breast Cancer Res Treat. 141:79–88. 2013. View Article : Google Scholar
36	Liang S, Guo R, Zhang Z, Liu D, Xu H, Xu Z, Wang X and Yang L: Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. Oncol Rep. 29:2422–2430. 2013.PubMed/NCBI